Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma

Gianni Bisogno, Andrea Ferrari, Arcangelo Prete, Chiara Messina, Eleonora Basso, Giovanni Cecchetto, Paolo Indolfi, Giovanni Scarzello, Paolo D'Angelo, Luigi De Sio, Andrea Di Cataldo, Modesto Carli

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Aim: The RMS4.99 study was designed to explore the role of multiple sequential high-dose chemotherapy cycles administered early in the treatment of children with metastatic rhabdomyosarcoma. Patients and methods: Seventy patients were enrolled and received three cycles of initial standard chemotherapy, followed by a course of cyclophosphamide and etoposide to obtain peripheral blood stem cells (PBSC), then three consecutive high-dose combinations followed by PBSC rescue. This was followed by surgery and/or radiotherapy, after which a final maintenance treatment with six courses of vincristine, actinomycin D and cyclophosphamide was administered. Results: Sixty-two patients underwent the high-dose chemotherapy phase. The 3-year overall survival (OS) and progression free survival (PFS) rates for the 70 patients were 42.3% (95% confidence interval [CI] 39.5-53.6) and 35.3% (95% CI, 24.3-46.5), respectively. By multivariate analysis survival correlated strongly with age > 10 years. In a subset of patients with only one or no unfavourable prognostic factors (age > 10 years, unfavourable site of primary tumour, bone or bone marrow involvement and number of metastatic sites >2) the PFS was significantly higher, i.e. 60.5% at 3 years. Conclusion: Our study confirms that patients with favourable prognostic characteristics have a better survival. The use of sequential cycles of high-dose chemotherapy did not appear of benefit for patients with metastatic rhabdomyosarcoma.

Original languageEnglish
Pages (from-to)3035-3041
Number of pages7
JournalEuropean Journal of Cancer
Volume45
Issue number17
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Rhabdomyosarcoma
Drug Therapy
Cyclophosphamide
Disease-Free Survival
Survival
Confidence Intervals
Dactinomycin
Vincristine
Etoposide
Radiotherapy
Multivariate Analysis
Survival Rate
Bone Marrow
Bone and Bones
Therapeutics
Neoplasms

Keywords

  • High-dose chemotherapy
  • Metastases
  • Rhabdomyosarcoma
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bisogno, G., Ferrari, A., Prete, A., Messina, C., Basso, E., Cecchetto, G., ... Carli, M. (2009). Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. European Journal of Cancer, 45(17), 3035-3041. https://doi.org/10.1016/j.ejca.2009.08.019

Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. / Bisogno, Gianni; Ferrari, Andrea; Prete, Arcangelo; Messina, Chiara; Basso, Eleonora; Cecchetto, Giovanni; Indolfi, Paolo; Scarzello, Giovanni; D'Angelo, Paolo; Sio, Luigi De; Di Cataldo, Andrea; Carli, Modesto.

In: European Journal of Cancer, Vol. 45, No. 17, 11.2009, p. 3035-3041.

Research output: Contribution to journalArticle

Bisogno, G, Ferrari, A, Prete, A, Messina, C, Basso, E, Cecchetto, G, Indolfi, P, Scarzello, G, D'Angelo, P, Sio, LD, Di Cataldo, A & Carli, M 2009, 'Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma', European Journal of Cancer, vol. 45, no. 17, pp. 3035-3041. https://doi.org/10.1016/j.ejca.2009.08.019
Bisogno, Gianni ; Ferrari, Andrea ; Prete, Arcangelo ; Messina, Chiara ; Basso, Eleonora ; Cecchetto, Giovanni ; Indolfi, Paolo ; Scarzello, Giovanni ; D'Angelo, Paolo ; Sio, Luigi De ; Di Cataldo, Andrea ; Carli, Modesto. / Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. In: European Journal of Cancer. 2009 ; Vol. 45, No. 17. pp. 3035-3041.
@article{969ca89bc01247479db0768413ef0232,
title = "Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma",
abstract = "Aim: The RMS4.99 study was designed to explore the role of multiple sequential high-dose chemotherapy cycles administered early in the treatment of children with metastatic rhabdomyosarcoma. Patients and methods: Seventy patients were enrolled and received three cycles of initial standard chemotherapy, followed by a course of cyclophosphamide and etoposide to obtain peripheral blood stem cells (PBSC), then three consecutive high-dose combinations followed by PBSC rescue. This was followed by surgery and/or radiotherapy, after which a final maintenance treatment with six courses of vincristine, actinomycin D and cyclophosphamide was administered. Results: Sixty-two patients underwent the high-dose chemotherapy phase. The 3-year overall survival (OS) and progression free survival (PFS) rates for the 70 patients were 42.3{\%} (95{\%} confidence interval [CI] 39.5-53.6) and 35.3{\%} (95{\%} CI, 24.3-46.5), respectively. By multivariate analysis survival correlated strongly with age > 10 years. In a subset of patients with only one or no unfavourable prognostic factors (age > 10 years, unfavourable site of primary tumour, bone or bone marrow involvement and number of metastatic sites >2) the PFS was significantly higher, i.e. 60.5{\%} at 3 years. Conclusion: Our study confirms that patients with favourable prognostic characteristics have a better survival. The use of sequential cycles of high-dose chemotherapy did not appear of benefit for patients with metastatic rhabdomyosarcoma.",
keywords = "High-dose chemotherapy, Metastases, Rhabdomyosarcoma, Soft tissue sarcoma",
author = "Gianni Bisogno and Andrea Ferrari and Arcangelo Prete and Chiara Messina and Eleonora Basso and Giovanni Cecchetto and Paolo Indolfi and Giovanni Scarzello and Paolo D'Angelo and Sio, {Luigi De} and {Di Cataldo}, Andrea and Modesto Carli",
year = "2009",
month = "11",
doi = "10.1016/j.ejca.2009.08.019",
language = "English",
volume = "45",
pages = "3035--3041",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "17",

}

TY - JOUR

T1 - Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma

AU - Bisogno, Gianni

AU - Ferrari, Andrea

AU - Prete, Arcangelo

AU - Messina, Chiara

AU - Basso, Eleonora

AU - Cecchetto, Giovanni

AU - Indolfi, Paolo

AU - Scarzello, Giovanni

AU - D'Angelo, Paolo

AU - Sio, Luigi De

AU - Di Cataldo, Andrea

AU - Carli, Modesto

PY - 2009/11

Y1 - 2009/11

N2 - Aim: The RMS4.99 study was designed to explore the role of multiple sequential high-dose chemotherapy cycles administered early in the treatment of children with metastatic rhabdomyosarcoma. Patients and methods: Seventy patients were enrolled and received three cycles of initial standard chemotherapy, followed by a course of cyclophosphamide and etoposide to obtain peripheral blood stem cells (PBSC), then three consecutive high-dose combinations followed by PBSC rescue. This was followed by surgery and/or radiotherapy, after which a final maintenance treatment with six courses of vincristine, actinomycin D and cyclophosphamide was administered. Results: Sixty-two patients underwent the high-dose chemotherapy phase. The 3-year overall survival (OS) and progression free survival (PFS) rates for the 70 patients were 42.3% (95% confidence interval [CI] 39.5-53.6) and 35.3% (95% CI, 24.3-46.5), respectively. By multivariate analysis survival correlated strongly with age > 10 years. In a subset of patients with only one or no unfavourable prognostic factors (age > 10 years, unfavourable site of primary tumour, bone or bone marrow involvement and number of metastatic sites >2) the PFS was significantly higher, i.e. 60.5% at 3 years. Conclusion: Our study confirms that patients with favourable prognostic characteristics have a better survival. The use of sequential cycles of high-dose chemotherapy did not appear of benefit for patients with metastatic rhabdomyosarcoma.

AB - Aim: The RMS4.99 study was designed to explore the role of multiple sequential high-dose chemotherapy cycles administered early in the treatment of children with metastatic rhabdomyosarcoma. Patients and methods: Seventy patients were enrolled and received three cycles of initial standard chemotherapy, followed by a course of cyclophosphamide and etoposide to obtain peripheral blood stem cells (PBSC), then three consecutive high-dose combinations followed by PBSC rescue. This was followed by surgery and/or radiotherapy, after which a final maintenance treatment with six courses of vincristine, actinomycin D and cyclophosphamide was administered. Results: Sixty-two patients underwent the high-dose chemotherapy phase. The 3-year overall survival (OS) and progression free survival (PFS) rates for the 70 patients were 42.3% (95% confidence interval [CI] 39.5-53.6) and 35.3% (95% CI, 24.3-46.5), respectively. By multivariate analysis survival correlated strongly with age > 10 years. In a subset of patients with only one or no unfavourable prognostic factors (age > 10 years, unfavourable site of primary tumour, bone or bone marrow involvement and number of metastatic sites >2) the PFS was significantly higher, i.e. 60.5% at 3 years. Conclusion: Our study confirms that patients with favourable prognostic characteristics have a better survival. The use of sequential cycles of high-dose chemotherapy did not appear of benefit for patients with metastatic rhabdomyosarcoma.

KW - High-dose chemotherapy

KW - Metastases

KW - Rhabdomyosarcoma

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=70350602712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350602712&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2009.08.019

DO - 10.1016/j.ejca.2009.08.019

M3 - Article

VL - 45

SP - 3035

EP - 3041

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 17

ER -